Enhanced Methods for the Use of 5'-Adenosine Diphosphate Ribose (ADPR)

Improved methods and compositions for treating adenovirus-related diseases or conditions using 5'-adenosine diphosphate ribose (ADPR), addressing the limitations of existing treatments.

The original patent disclosed methods for using ADPR to treat adenovirus-related diseases or conditions, but had limitations in terms of efficacy, delivery, and side effects. The new inventive concept addresses these limitations by introducing novel systems, methods, and compositions that enhance the treatment of adenovirus-related diseases or conditions using ADPR.

The new inventive concept comprises four main aspects: (1) a system for treating adenovirus-related diseases or conditions using a topical administration device, (2) a method for enhancing the efficacy of ADPR by dividing the daily dose into multiple sub-doses, (3) a pharmaceutical composition that includes a penetration enhancer to facilitate delivery across epithelial or mucosal barriers, and (4) a system for monitoring the efficacy of ADPR using a biosensor. These aspects work together to provide a more effective and efficient treatment for adenovirus-related diseases or conditions.

The new inventive concept introduces novel systems, methods, and compositions that are not obvious from the original patent. The use of a topical administration device, divided daily doses, penetration enhancers, and biosensors for monitoring efficacy are all new and non-obvious features that improve the treatment of adenovirus-related diseases or conditions using ADPR.

Alternative embodiments of the inventive concept could include different types of administration devices, varying the frequency and timing of sub-doses, using different penetration enhancers, or incorporating additional components to enhance efficacy. These variations could be used to tailor the treatment to specific patient needs or to address different types of adenovirus-related diseases or conditions.

The enhanced methods and compositions for treating adenovirus-related diseases or conditions using ADPR have significant commercial potential in the pharmaceutical and biotechnology industries. The target market includes patients suffering from adenovirus-related diseases or conditions, as well as healthcare providers and researchers seeking more effective treatments.